JP2024543379A5 - - Google Patents

Info

Publication number
JP2024543379A5
JP2024543379A5 JP2024527357A JP2024527357A JP2024543379A5 JP 2024543379 A5 JP2024543379 A5 JP 2024543379A5 JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024543379 A5 JP2024543379 A5 JP 2024543379A5
Authority
JP
Japan
Prior art keywords
psilocybin
dose
weeks
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/048713 external-priority patent/WO2023086252A1/en
Publication of JP2024543379A publication Critical patent/JP2024543379A/ja
Publication of JP2024543379A5 publication Critical patent/JP2024543379A5/ja
Pending legal-status Critical Current

Links

JP2024527357A 2021-11-09 2022-11-02 サイロシビンによる治療抵抗性うつ病の治療 Pending JP2024543379A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277407P 2021-11-09 2021-11-09
US63/277,407 2021-11-09
US202163284973P 2021-12-01 2021-12-01
US63/284,973 2021-12-01
PCT/US2022/048713 WO2023086252A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Publications (2)

Publication Number Publication Date
JP2024543379A JP2024543379A (ja) 2024-11-21
JP2024543379A5 true JP2024543379A5 (cg-RX-API-DMAC7.html) 2025-10-24

Family

ID=84799979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527357A Pending JP2024543379A (ja) 2021-11-09 2022-11-02 サイロシビンによる治療抵抗性うつ病の治療

Country Status (8)

Country Link
US (1) US20250000881A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429671A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543379A (cg-RX-API-DMAC7.html)
KR (1) KR20240110816A (cg-RX-API-DMAC7.html)
AU (1) AU2022387053A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237885A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005632A (cg-RX-API-DMAC7.html)
WO (1) WO2023086252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2588505B (en) * 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.

Similar Documents

Publication Publication Date Title
JP2023123773A5 (cg-RX-API-DMAC7.html)
JP2008535867A5 (cg-RX-API-DMAC7.html)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
KR20210117345A (ko) Jak 저해제를 포함하는 제약 조성물
JP2014516942A5 (cg-RX-API-DMAC7.html)
BG61678B1 (bg) Антиисхемично лекарствено средство
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2025508071A5 (cg-RX-API-DMAC7.html)
JP2024544538A5 (cg-RX-API-DMAC7.html)
JP2025515671A5 (cg-RX-API-DMAC7.html)
JP2023526517A5 (cg-RX-API-DMAC7.html)
CA2306985A1 (en) Novel use of compounds for anti-pruritic activity
JP2024509193A5 (cg-RX-API-DMAC7.html)
JP2025509278A5 (cg-RX-API-DMAC7.html)
JP2025508051A5 (cg-RX-API-DMAC7.html)
JP2025504219A5 (cg-RX-API-DMAC7.html)
TW202237103A (zh) 用於治療抑鬱症的nr2b-nmda受體nam之劑量方案
TW493985B (en) pharmaceutical composition for the treatment of herpes simplex infections comprising famciclovir/penciclovir in combination with an immunosuppressant
ES2957232T3 (es) Composiciones para el tratamiento o la prevención de síntomas vasomotores
ES2309357T3 (es) Nueva combinacion sinergica que comprende roflumilast y formoterol.
Brunner et al. Effectiveness of sustained-action isosorbide dinitrate on exercise-induced myocardial ischemia
JP2023527358A5 (cg-RX-API-DMAC7.html)
JP2022518288A5 (cg-RX-API-DMAC7.html)
JP2024518779A (ja) ミタピバットを滴定するための方法
JPH0680564A (ja) 抗色素沈着治療薬